Ab­b­Vie rais­es Skyrizi and Rin­voq es­ti­mates, pre­dicts $31B in 2027 sales

The loss of Hu­mi­ra ex­clu­siv­i­ty was long ex­pect­ed to be a blow to Ab­b­Vie’s im­munol­o­gy dom­i­nance, but the Skyrizi-Rin­voq tan­dem keeps out­pac­ing ex­pec­ta­tions.

In its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER